Download biomedica product list
Our ELISA Kits Go Global
We operate in more than 60 countries, providing wide access and customer support through collaborations with carefully chosen local distributors on nearly every continent. No matter where you are, we’re committed to helping you achieve your objectives. With over 30 years of expertise, we focus on designing and manufacturing premium ELISA assay kits for biomarker detection in clinical research.
About us
We develop and produce high-quality ELISA assay kits for clinical and pre-clinical applications related to bone and cardio-renal diseases. Our assays are cited in more than 2500 publications and some of our kits are the most referenced on the market Sclerostin, free soluble RANKL, Periostin, NT-proCNP and many others.
Our ELISA Kits Go Global
All Biomedica ELISA assays undergo a full validation following international quality guidelines (the validation package for every kit can be found on the respective product pages on our website. Validation criteria include recovery, dilution linearity, parallelism, matrix effect testing and many others.
Our ELISA kits include ready-to-use serum-based calibrators and controls enabling researchers to collect biologically reliable data.
Features & Benefits of BIOMEDICA ELISA Assay Kits
- Trusted – cited in over 2500 publications
- Highly specific – characterized epitope-mapped antibodies
- Full validation package – following international quality guidelines
- Convenient – ready to use, color coded reagents – controls included
Biomarker ELISA Assays for Bone-Mineral Metabolism & Cardio-Renal Diseases
–Intact FGF23 ELISA Kit | BI-20700
–FGF23 (C-terminal) multi-matrix ELISA Kit | BI-20702
–FREE soluble RANKL HS ELISA | BI-20462
–OPG ELISA Kit (Human Osteoprotegerin) | BI-20403
–Rat NT-proBNP ELISA | BI-1204R
Selected citations
Fibroblast Growth Factor 23, Endogenous Erythropoietin, Erythropoiesis-Stimulating Agents, and Erythropoietin Resistance in Hemodialysis Patients. Hamano N et al.,2025; Am J Nephrol.
Fibroblast growth factor 23 is associated with the development of gestational diabetes mellitus. Hocher CF et al., 2023; Diabetes Metab Res Rev.
The effect of calcium supplementation on bone calcium balance and calcium and bone metabolism during load carriage in women: a randomised controlled crossover trial. Coombs CV et al., 2025; J Bone Miner Res.
Bone proteins are associated with cardiovascular risk according to the SCORE2-Diabetes algorithm. González-Salvatierra S et a., 2024; Cardiovasc Diabetol.